Paper40568599
Risk scoring model for lung adenocarcinoma based on PD-L1 related signature reveals prognostic predictability and correlation with tumor immune microenvironment genes was constructed.
Li-Fei M and 5 others. Front Immunol, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Risk scoring model for lung adenocarcinoma based on PD-L1 related signature reveals prognostic predictability and correlation with tumor immune microenvironment genes was constructed. Papers, record 40568599. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40568599
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Risk scoring model for lung adenocarcinoma based on PD-L1 related signature reveals prognostic predictability and correlation with tumor immune microenvironment genes was constructed.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Adenocarcinoma of Lung | Major topic |
| Lung Neoplasms | Major topic |
| B7-H1 Antigen | Major topic |
| Biomarkers, Tumor | Major topic |
| Humans | |
| Prognosis | |
| Gene Expression Regulation, Neoplastic | |
| Gene Expression Profiling | |
| Male | |
| Female | |
| Databases, Genetic |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36934264 | Exosomal MFI2-AS1 sponge miR-107 promotes non-small cell lung cancer progression through NFAT5. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/36934264 | PubMed |
| 2 | 38333021 | SPRR1B is Related to the Immune Microenvironment and Can Be Used as a Biomarker for the Diagnosis of Psoriasis. | Int J Gen Med | 2024 | https://conductscience.org/library/papers/38333021 | PubMed |
| 3 | 32919526 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32919526 | PubMed |
| 4 | 32001626 | Neoadjuvant checkpoint blockade for cancer immunotherapy. | Science | 2020 | https://conductscience.org/library/papers/32001626 | PubMed |
| 5 | 33501784 | Identification of small proline-rich protein 1B (SPRR1B) as a prognostically predictive biomarker for lung adenocarcinoma by integrative bioinformatic analysis. | Thorac Cancer | 2021 | https://conductscience.org/library/papers/33501784 | PubMed |
| 6 | 30654138 | An extensive experimental survey of regression methods. | Neural Netw | 2019 | https://conductscience.org/library/papers/30654138 | PubMed |
| 7 | 31623662 | Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31623662 | PubMed |
| 8 | 30171052 | Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. | Cancer Res | 2018 | https://conductscience.org/library/papers/30171052 | PubMed |
| 9 | 39892819 | Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity. | J Hepatol | 2025 | https://conductscience.org/library/papers/39892819 | PubMed |
| 10 | 28039262 | Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28039262 | PubMed |
| 11 | 38909843 | Melanotransferrin (MELTF, MFI2, CD228) Expression Attenuates Malignant Melanoma Progression in the A375-Luc2 Murine Metastasis Model and Human Patients. | J Invest Dermatol | 2024 | https://conductscience.org/library/papers/38909843 | PubMed |
| 12 | 36800443 | SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models. | Mol Cancer Ther | 2023 | https://conductscience.org/library/papers/36800443 | PubMed |
| 13 | 21190562 | PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. | Mol Cancer | 2010 | https://conductscience.org/library/papers/21190562 | PubMed |
| 14 | 37814076 | Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma. | Cell Oncol (Dordr) | 2024 | https://conductscience.org/library/papers/37814076 | PubMed |
| 15 | 34112123 | GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma. | BMC Pulm Med | 2021 | https://conductscience.org/library/papers/34112123 | PubMed |
| 16 | 39901895 | CD25 downregulation by tumor exosomal microRNA-15a promotes interleukin-17-producing γδ-T-cells-mediated radioresistance in nasopharyngeal carcinoma. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/39901895 | PubMed |
| 17 | 38410229 | Sinensetin suppresses breast cancer cell progression via Wnt/β-catenin pathway inhibition. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/38410229 | PubMed |
| 18 | 40081220 | Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs. | Drug Resist Updat | 2025 | https://conductscience.org/library/papers/40081220 | PubMed |
| 19 | 33127882 | The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/33127882 | PubMed |
| 20 | 29749538 | TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma. | Oncol Rep | 2018 | https://conductscience.org/library/papers/29749538 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42614290 | New insights into lysosomal ferroptosis-related prognostic signatures in prostate cancer: evidence from bulk and single-cell transcriptomic analysis. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42614290 | PubMed |
| 42544237 | PTM-Related Signatures Predict Lymph Node Metastasis and Shape Microenvironment in Hepatocellular Carcinoma: A Single-Cell and Bulk Integrated Analysis. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42544237 | PubMed |
| 42401850 | Machine learning-driven development of a novel unfolded protein response-related gene signature for predicting lung adenocarcinoma patient prognosis. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42401850 | PubMed |
| 42196541 | Integrative Bulk and Single-Cell Transcriptomic Analysis Identifies a Hypoxia- and Lipid Metabolism-Related Prognostic Signature in Oral Squamous Cell Carcinoma: A Retrospective Study. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196541 | PubMed |
| 42180240 | Association between duration of dysphagia and dysphonia with insomnia: results from the National Health Interview Survey. | Front Neurol | 2026 | https://conductscience.org/library/papers/42180240 | PubMed |
| 41968824 | AR and ITGAL: Key Mediators of Andrographis paniculata's Anti-Psoriatic Effects Revealed by Multi-Omics Analysis. | Comb Chem High Throughput Screen | 2026 | https://conductscience.org/library/papers/41968824 | PubMed |
| 41899571 | An Analysis of G3BP2 in Non-Small Cell Lung Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899571 | PubMed |
| 41634312 | Integrative analysis of transcriptome and single-cell sequencing combined with experimental validation identifies biomarkers associated with T cell and senescence in sepsis. | Sci Rep | 2026 | https://conductscience.org/library/papers/41634312 | PubMed |
| 40787424 | Development and validation of transient receptor potential channel-related signature for predicting prognosis in patients with lung adenocarcinoma. | Oncol Lett | 2025 | https://conductscience.org/library/papers/40787424 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADGRF4 | 221393 | PubTator's text mining | https://conductscience.org/library/genes/221393 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| GREB1L | 80000 | PubTator's text mining | https://conductscience.org/library/genes/80000 | NCBI Gene |
| IL17A | 3605 | PubTator's text mining | https://conductscience.org/library/genes/3605 | NCBI Gene |
| LIPK | 643414 | PubTator's text mining | https://conductscience.org/library/genes/643414 | NCBI Gene |
| SPRR1B | 6699 | PubTator's text mining | https://conductscience.org/library/genes/6699 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40568599
GET https://conductscience.org/api/papers/v1/40568599/references?page=2